- Home
- UPXI vs ERAS Comparison
UPXI vs ERAS Comparison
Compare UPXI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- ERAS
- Stock Information
- Founded
- UPXI 2018
- ERAS 2018
- Country
- UPXI United States
- ERAS United States
- Employees
- UPXI N/A
- ERAS N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- ERAS Health Care
- Exchange
- UPXI Nasdaq
- ERAS Nasdaq
- Market Cap
- UPXI 356.9M
- ERAS 348.4M
- IPO Year
- UPXI 2021
- ERAS 2021
- Fundamental
- Price
- UPXI $5.39
- ERAS $1.45
- Analyst Decision
- UPXI
- ERAS Strong Buy
- Analyst Count
- UPXI 0
- ERAS 6
- Target Price
- UPXI N/A
- ERAS $4.83
- AVG Volume (30 Days)
- UPXI 4.2M
- ERAS 1.2M
- Earning Date
- UPXI 05-16-2025
- ERAS 08-11-2025
- Dividend Yield
- UPXI N/A
- ERAS N/A
- EPS Growth
- UPXI N/A
- ERAS N/A
- EPS
- UPXI N/A
- ERAS N/A
- Revenue
- UPXI $16,562,327.00
- ERAS N/A
- Revenue This Year
- UPXI $299.03
- ERAS N/A
- Revenue Next Year
- UPXI N/A
- ERAS N/A
- P/E Ratio
- UPXI N/A
- ERAS N/A
- Revenue Growth
- UPXI 1378.83
- ERAS N/A
- 52 Week Low
- UPXI $1.90
- ERAS $1.01
- 52 Week High
- UPXI $22.57
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- UPXI 44.83
- ERAS 52.19
- Support Level
- UPXI $2.73
- ERAS $1.38
- Resistance Level
- UPXI $3.47
- ERAS $1.58
- Average True Range (ATR)
- UPXI 0.69
- ERAS 0.11
- MACD
- UPXI 0.14
- ERAS 0.01
- Stochastic Oscillator
- UPXI 36.97
- ERAS 64.86
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.